Provided by Tiger Trade Technology Pte. Ltd.

Corcept Therapeutics

115.55
-0.1500-0.13%
Volume:88.01K
Turnover:10.19M
Market Cap:12.49B
PE:254.71
High:116.97
Open:114.42
Low:113.20
Close:115.70
52wk High:126.38
52wk Low:28.66
Shares:108.10M
Float Shares:96.44M
Volume Ratio:0.51
T/O Rate:0.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4537
EPS(LYR):0.8200
ROE:8.23%
ROA:0.47%
PB:17.70
PE(LYR):140.91

Loading ...

Corcept CFO Atabak Mokari sells common shares worth $3.22 million

Reuters
·
Jun 18

Corcept Therapeutics resubmits NDA for Relacorilant in Cushing’s Syndrome

TIPRANKS
·
Jun 18

Corcept resubmits FDA NDA for relacorilant in Cushing’s syndrome, expects six-month review

Reuters
·
Jun 18

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients With Cushing’s Syndrome

THOMSON REUTERS
·
Jun 18

Corcept Therapeutics - Resubmission Includes Additional Analyses; Expects Six-Month FDA Review

THOMSON REUTERS
·
Jun 18

Corcept Therapeutics (CORT) Valuation After New Korlym CATALYST And MOMENTUM Trial Data

Simply Wall St.
·
Jun 10

Corcept announces presentation of new data from Catalyst, Momentum trials

TIPRANKS
·
Jun 08

Lifyorli Survival Data and DOJ Update Might Change The Case For Investing In Corcept Therapeutics (CORT)

Simply Wall St.
·
Jun 07

Corcept Chief Development Officer William Guyer disposes of 20,000 common shares for $1.41 million

Reuters
·
Jun 05

Corcept Endocrinology President Sean Maduck disposes of Corcept Therapeutics shares worth $1.75 million

Reuters
·
Jun 04

Corcept CFO Atabak Mokari sells 40,000 shares for USD 2.8 million

Reuters
·
Jun 04

Corcept Therapeutics - DOJ, California Department of Insurance, and Plaintiff States Decline to Intervene in Lawsuit - SEC Filing

THOMSON REUTERS
·
Jun 03

Corcept Therapeutics Inc: Intends to Defend Against All of Relator's Claims

THOMSON REUTERS
·
Jun 03

Corcept Therapeutics - DOJ Previously Issued Records Subpoena to Corcept in Nov 2021 Regarding Korlym Sales and Promotion - SEC Filing

THOMSON REUTERS
·
Jun 03

Corcept Therapeutics - Relator Serves Corcept With Amended Complaint on June 2, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 03

Corcept says DOJ declines to intervene in Korlym-related qui tam lawsuit

Reuters
·
Jun 03

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 01

Corcept Chief Accounting & Technology Officer Joseph Douglas Lyon sells 5,000 shares for $325,000

Reuters
·
May 30

Corcept Endocrinology President Sean Maduck sells USD 4.92 million Corcept Therapeutics shares

Reuters
·
May 30

Corcept Therapeutics holds annual shareholder meeting, backs amended 2024 incentive plan

Reuters
·
May 29